On March 8, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported the dosing of the first uveal and cutaneous melanoma patients with pegzilarginase (AEB1102) in its open-label Phase 1 cohort expansions (Press release, Aeglea BioTherapeutics, MAR 8, 2018, View Source [SID1234524966]). The Company expects to report topline data, including safety and clinical activity, in the fourth quarter of 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Given our encouraging dose escalation data with pegzilarginase, the start of these Phase 1 cohort expansions is an important next step in targeting the advanced solid tumors that we believe are vulnerable to arginine depletion," said Anthony Quinn, MB ChB, Ph.D., interim chief executive officer of Aeglea. "This is an exciting time at Aeglea as we assess the clinical activity of sustained arginine depletion in melanoma. We expect to report topline data in the fourth quarter of this year."

Aeglea also initiated studies with pegzilarginase in small cell lung cancer as monotherapy and in combination with pembrolizumab. Additionally, the Company is conducting an open-label Phase 1/2 trial and a long term extension study in patients with Arginase 1 Deficiency, a rare genetic disease. Regarding Arginase 1 Deficiency, Aeglea plans to report adult repeat dose data this month and adult and pediatric repeat dose data, along with pivotal trial design, in the second half of this year.

On March 7, 2018Clovis Oncology, Inc. (Nasdaq: CLVS) reported that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time (Press release, Clovis Oncology, MAR 7, 2018, View Source;p=RssLanding&cat=news&id=2336864 [SID1234524501]). The conference will be held at the Loews Miami Beach Hotel in Miami.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

On March 7, 2018 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that it will release its financial results for fourth quarter and fiscal year 2017 after the close of trading on Wednesday, March 14, 2018 (Press release, Quanterix, MAR 7, 2018, View Source [SID1234524521]). Company management will host a conference call at 4:30 p.m. EDT to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following password: 5079049. A live webcast will be accessible on the Investors section of Quanterix’ website: View Source The webcast will be available on the Company’s website for one year following completion of the call.

On March 7, 2018 Novavax, Inc. (Nasdaq:NVAX) reported it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March 14, 2018 (Press release, Novavax, MAR 7, 2018, http://ir.novavax.com/news-releases/news-release-details/novavax-host-conference-call-and-webcast-provide-corporate [SID1234524619]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call and webcast details are as follows:

Date: March 14, 2018

Time: 5:00 p.m. U.S. Eastern Time (ET)

Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)

Passcode: 6472939

Webcast: www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 8:00 p.m. ET, March 14, 2018 until

9:00 p.m. ET March 21, 2018

Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode: 6472939

Webcast: www.novavax.com, "Investors"/ "Events", until June 14

On March 7, 2018 The University of Texas MD Anderson Cancer Center and Berkeley Lights, Inc. reported the launch of Optera Therapeutics Corp, a biopharmaceutical company developing cell therapies with scalable manufacturing solutions for cancer (Press release, Optera Therapeutics, MAR 7, 2018, View Source [SID1234525317]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell-based immunotherapies where patients are treated with their own immune cells, such as chimeric antigen receptor (CAR-T) and T cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes (TIL) and endogenous T cells (ETC), have demonstrated promise for treating cancer. Optera Therapeutics will develop cancer cell therapies discovered at MD Anderson and apply Berkeley Lights’ advanced cell therapy manufacturing systems with the goal of making these novel therapies accessible to all.

"MD Anderson is dedicated to improving the standard of care for our patients as we strive to realize our mission to end cancer," said Patrick Hwu, M.D., division head of Cancer Medicine. "Our hope is that – by combining our cell therapy research expertise with advanced automation capabilities – we will enhance our ability to deliver these treatments to every patient who needs them."

Optera Therapeutics is developing cell therapies under investigation at MD Anderson by leaders in the field of cellular immunology including Cassian Yee, M.D., professor of Melanoma Medical Oncology; Katy Rezvani, M.D., Ph.D., Chief, Section of Cellular Therapy at Department of Stem Cell Transplantation and Cellular Therapy; Elizabeth Shpall, M.D., professor of Stem Cell Transplantation and Cellular Therapy; Chantale Bernatchez, Ph.D., assistant professor of Melanoma Medical Oncology; Sattva Neelapu, M.D., professor of Lymphoma and Myeloma; and Greg Lizee, Ph.D., associate professor, Department of Melanoma Medical Oncology.

"Cell therapy is transforming the standard of care for cancer patients," said Yee. "Optera will capitalize on truly disruptive technology and allow us to extend our ability to treat more patients, for more cancers, in a shorter period of time."

Eric Hobbs, chief executive officer of Berkeley Lights, Inc., added, "The Berkeley Lights team is privileged and excited to join forces with our colleagues at MD Anderson who have devoted their lives to defeating cancer. We are absolutely driven to make their life-saving cell therapies accessible to all."